Alimera Sciences, Inc.
(NASDAQ : ALIM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Loading ALIM News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.18%165.741.2%$762.85m
INCYIncyte Corporation
0.48%139.641.7%$625.40m
GILDGilead Sciences, Inc.
0.03%67.511.0%$573.84m
CELGCelgene Corporation
0.13%123.381.0%$496.94m
BIIBBiogen Inc.
-0.21%274.821.3%$454.02m
REGNRegeneron Pharmaceuticals, Inc.
2.19%373.002.1%$318.70m
KITEKite Pharma, Inc.
3.14%76.8418.8%$216.10m
ALXNAlexion Pharmaceuticals, Inc.
-0.83%119.261.6%$202.32m
TSROTESARO, Inc.
4.15%160.0016.1%$185.28m
ILMNIllumina, Inc.
1.72%170.583.7%$170.76m
ESPREsperion Therapeutics, Inc.
-3.61%38.9418.7%$166.57m
AUPHAurinia Pharmaceuticals Inc.
-4.41%8.026.3%$143.97m
CLVSClovis Oncology, Inc.
2.61%70.3217.5%$141.44m
VRTXVertex Pharmaceuticals Incorporated
1.04%89.982.2%$134.68m
EXELExelixis, Inc.
2.95%20.917.0%$105.35m

Company Profile

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its portfolio includes ILUVIEN and NADPH Oxidase Inhibitors. The company was founded on June 4, 2003 by Daniel C. Myers and David R. Holland and is headquartered in Alpharetta, GA.